Table of Contents
Overview
New York, NY – Oct 17, 2025 – The Global Blood Screening Market size is expected to be worth around USD 6.4 billion by 2033 from USD 2.9 billion in 2024, growing at a CAGR of 9.0% during the forecast period 2025 to 2033.
The global Blood Screening market is experiencing significant growth, driven by the rising prevalence of infectious diseases and the increasing demand for safe blood transfusion procedures. Blood screening plays a vital role in detecting infections such as HIV, hepatitis B and C, and syphilis, ensuring the safety of donated blood before transfusion. The growing emphasis on improving healthcare infrastructure and enhancing diagnostic accuracy has further strengthened market expansion.
Technological advancements in nucleic acid testing (NAT), enzyme-linked immunosorbent assays (ELISA), and rapid testing methods are enhancing the efficiency and reliability of screening procedures. These innovations are widely adopted by hospitals, blood banks, and diagnostic laboratories to minimize the risk of transfusion-transmitted infections.
The market growth is also supported by increasing blood donations, government initiatives promoting blood safety, and rising awareness regarding early disease detection. Developed regions such as North America and Europe continue to lead the market due to advanced testing technologies and strong regulatory frameworks. Meanwhile, the Asia-Pacific region is projected to witness the fastest growth, attributed to improving healthcare access and higher investments in laboratory automation.
Major market players are focusing on product innovation, strategic collaborations, and regulatory approvals to expand their global presence. The overall outlook for the Blood Screening market remains positive, with sustained demand expected from both public and private healthcare sectors aiming to ensure safer, faster, and more efficient blood testing practices worldwide.
Key Takeaways
- Market Size: The Global Blood Screening Market size is expected to be worth around USD 6.4 billion by 2033 from USD 2.9 billion in 2024, growing at a CAGR of 9.0% during the forecast period 2025 to 2033.
- Market Growth: The market is anticipated to grow at a compound annual growth rate (CAGR) of 9.0% between 2024 and 2033, driven by advancements in diagnostic technologies and increasing demand for safe blood transfusions.
- Technology Analysis: The Nucleic Acid Amplification Test (NAT) segment dominated the market in 2023, accounting for 33.4% of the total revenue, owing to its superior sensitivity and ability to detect early-stage infections.
- Product Analysis: Reagents accounted for a substantial 65.2% market share in 2023 and are projected to record the fastest CAGR throughout the forecast period, supported by consistent usage in screening assays.
- End-Use Analysis: The independent clinical laboratories segment held the largest revenue share of 48.2% in 2023, reflecting the growing outsourcing of diagnostic services and adoption of automated screening systems.
- Regional Analysis: North America led the global market, capturing a notable 50% share in 2023, attributed to advanced healthcare infrastructure, strong regulatory frameworks, and high awareness of blood safety protocols.
Blood Screening Statistics
- Blood Donations and Transfusions: Globally, approximately 118.5 million blood donations are collected each year, with 40% of these originating from high income countries, which represent only 16% of the global population. In low income nations, nearly 54% of blood transfusions are administered to children under the age of five, whereas in high income countries, individuals aged over 60 years account for up to 76% of all transfusions.
- Blood Donation Rates by Income Group: In high income countries, the blood donation rate stands at 31.5 donations per 1,000 people. Upper middle income countries report a rate of 16.4 per 1,000, while lower middle and low income countries record significantly lower rates of 6.6 and 5.0 donations per 1,000 people, respectively.
- Voluntary Unpaid Blood Donations: Between 2008 and 2018, voluntary unpaid blood donations increased by 10.7 million units worldwide. Currently, 79 countries collect more than 90% of their blood supply from voluntary, unpaid donors, reflecting growing awareness and participation in blood donation initiatives.
- Plasma Derived Medicinal Products (PDMP): Out of 171 reporting countries, only 56 produce plasma derived medicinal products through plasma fractionation. The median plasma volume available for fractionation is 5.2 liters per 1,000 population, though significant disparities exist among countries.
- Gender Distribution in Blood Donations: Women contribute approximately 33% of global blood donations, though participation rates vary widely depending on regional healthcare practices, cultural norms, and donation accessibility.
- Screening and Safety Measures: In high income countries, nearly 99.8% of blood donations undergo screening according to standardized quality procedures, compared to 83% in lower middle income nations. The prevalence of HIV in donated blood remains minimal around 0.002% in high income regions while it may reach up to 0.70% in low income countries, highlighting ongoing disparities in blood safety and screening efficiency.
Regional Analysis
North America accounted for the largest revenue share of 37.5% in the global Blood Screening Market, driven by multiple factors. The region’s leadership is attributed to the strong presence of key industry players such as Abbott, Roche Diagnostics, and Danaher, coupled with the widespread adoption of advanced blood screening technologies. Stringent FDA regulations ensuring transfusion safety, well-established research and development infrastructure, and favorable reimbursement policies have further strengthened the regional market position.
Additionally, the high incidence of chronic diseases such as diabetes and cancer continues to elevate the demand for blood screening services. According to data published by the American Cancer Society (2022), approximately 1,918,030 new cancer cases and 609,360 related deaths were projected in the United States, underscoring the need for enhanced diagnostic and screening measures.
The Asia-Pacific region is projected to record the fastest growth rate during the forecast period. This growth is supported by rising public awareness of blood donation, improving patient affordability, and increasing industry focus on emerging markets. Countries such as India, China, Japan, Singapore, and Australia are key contributors to regional expansion.
In particular, India exhibits strong potential due to its relatively flexible regulatory framework, high import activity for diagnostic equipment, and growing private and foreign investments in healthcare infrastructure. The country’s extensive network of clinical laboratories and hospitals further facilitates rapid adoption of blood screening technologies, making testing more accessible and affordable across diverse patient segments.
Frequently Asked Questions on Blood Screening
- What is blood screening?
Blood screening is a medical testing process used to detect infectious agents or abnormalities in donated blood. It ensures transfusion safety by identifying viruses like HIV, hepatitis B and C, and other blood-borne pathogens before use. - Why is blood screening important?
Blood screening is vital to prevent transfusion-transmitted infections. It safeguards patients by ensuring only pathogen-free blood is used in medical procedures, reducing the risks associated with infectious diseases and promoting overall public health safety. - What technologies are used in blood screening?
Common technologies include enzyme-linked immunosorbent assay (ELISA), nucleic acid amplification test (NAT), chemiluminescent immunoassay, and rapid testing kits. These methods enhance detection accuracy, enabling early identification of infections in blood samples. - Who performs blood screening tests?
Blood screening tests are primarily conducted by hospitals, diagnostic laboratories, blood banks, and independent clinical laboratories. These institutions follow stringent regulatory standards to ensure reliable testing and safe blood transfusion practices. - What infections are commonly detected through blood screening?
Blood screening identifies infections such as HIV, hepatitis B and C, syphilis, malaria, and Zika virus. The tests are designed to detect viral, bacterial, and parasitic pathogens that can compromise transfusion safety. - What is driving the growth of the blood screening market?
The market growth is driven by rising demand for safe blood transfusions, increasing prevalence of infectious diseases, technological advancements in testing methods, and growing healthcare investments across both developed and developing regions. - Which region leads the global blood screening market?
North America leads the market, holding the highest revenue share due to advanced healthcare infrastructure, presence of major industry players, and strict regulatory frameworks ensuring high standards in blood safety. - Who are the key players in the blood screening market?
Major players include Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, Grifols S.A., and Danaher Corporation. These companies focus on technological innovation, partnerships, and regulatory compliance to strengthen their global presence. - Which end-use segment contributes most to market revenue?
Independent clinical laboratories dominate the end-use segment, accounting for nearly half of total revenue, driven by increasing test outsourcing and adoption of automated blood screening platforms for efficient large-scale testing.
Conclusion
The global Blood Screening market is poised for substantial growth, driven by the increasing prevalence of infectious diseases and the rising need for safe blood transfusions. Advancements in diagnostic technologies such as NAT and ELISA have significantly improved accuracy and efficiency, promoting wider adoption across hospitals and laboratories.
North America dominates the market due to strong healthcare infrastructure, while the Asia-Pacific region is projected to witness the fastest growth supported by expanding healthcare access and investments. Key players are focusing on innovation and strategic partnerships to enhance market reach.
Overall, the market outlook remains optimistic, underpinned by continuous technological progress, growing awareness of blood safety, and increasing global efforts toward reliable transfusion practices.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
